Beijing Biostar Pharmaceuticals Co., Ltd. (BIOSTAR) announced that its external auditor anticipates issuing a qualified opinion on the consolidated financial statements for the year ended 31 December 2025.
The board is currently engaging with the auditor to resolve the matters leading to the expected qualification. Detailed information will be provided in the forthcoming FY2025 annual results release.
The company advised shareholders and potential investors to exercise caution when trading its shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments